Concepedia

Author

Samuel E. DePrimo

Pfizer (United States)

Also Known As

S E DePrimo, S. DePrimo, S. Deprimo, S. E. Deprimo, S.E DePrimo, S.E. DePrimo, Samuel DePrimo, Samuel Deprimo, Samuel E DePrimo, Samuel E. DePrimo

54

Publications

6.7K

Citations

29

H-Index

34

Concepts

All Affiliations

Pfizer (United States)Janssen (United States)Dana-Farber Cancer InstituteMemorial Sloan Kettering Cancer CenterStanford University
SE

About

Samuel E. DePrimo is an author at Pfizer (United States) specializing in medicine, cell biology, and gene expression.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

1.1K

2

Cell Biology

5

5

365

3

Endocrinology

1

1

46

4

Hepatology

1

1

288

5

Immunology

1

1

67

Samuel E. DePrimo

×

34

Publications

6.6K

Citations

28

H-Index

YearCitations

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

Robert J. Motzer, M. Dror Michaelson, Bruce G. Redman,

Journal of Clinical Oncology

2005

1.6K

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

Sandrine Faivre, Catherine Delbaldo, Karina Vera,

Journal of Clinical Oncology

2005

1.1K

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Harold J. Burstein, Anthony Elias, Hope S. Rugo,

Journal of Clinical Oncology

2008

483

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

Brian I. Rini, M. Dror Michaelson, Jonathan E. Rosenberg,

Journal of Clinical Oncology

2008

392

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

Suzanne George, Jean‐Yves Blay, Paolo G. Casali,

European Journal of Cancer

2009

365

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

Samuel E. DePrimo, Carlo L. Bello, John Smeraglia,

Journal of Translational Medicine

2007

320

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

Sandrine Faivre, Éric Raymond, Éveline Boucher,

The Lancet Oncology

2009

288

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers

Patricia LoRusso, Smitha Krishnamurthi, John J. Rinehart,

Clinical Cancer Research

2010

247

Mechanisms of G2 Arrest in Response to Overexpression of p53

William R. Taylor, Samuel E. DePrimo, Archana M. Agarwal,

Molecular Biology of the Cell

1999

194

Transcriptional programs activated by exposure of human prostate cancer cells to androgen

Samuel E. DePrimo, Maximilian Diehn, Joel B. Nelson,

Genome biology

2002

192

Page 1